PMID- 28862769
OWN - NLM
STAT- MEDLINE
DCOM- 20190327
LR  - 20190327
IS  - 1526-4610 (Electronic)
IS  - 0017-8748 (Linking)
VI  - 58
IP  - 1
DP  - 2018 Jan
TI  - Histamine and Migraine.
PG  - 184-193
LID - 10.1111/head.13164 [doi]
AB  - BACKGROUND: Histamine is an ancient "tissue amine" preceding multicellular 
      organisms. In the central nervous system (CNS), its fibers originate solely from 
      the tuberomammillary nucleus and travel throughout the brain. It is mainly 
      responsible for wakefulness, energy homeostasis, and memory consolidation. 
      Recently, several studies suggest a potential role of histamine in migraine 
      pathogenesis and management. METHODS: Narrative review of current literature 
      regarding histamine and migraine. RESULTS: Histamine plays a crucial role in 
      migraine pathogenesis: sustaining the neurogenic inflammation pathway. 
      Interaction between mast cells (MC) and calcitonin-gene related protein (CGRP) 
      results in sensitization of trigeminal afferents and trigeminal ganglia (TG). 
      Histamine binds with differing affinities to four different histaminergic 
      G-protein coupled receptors, activating protein kinases, or triggering calcium 
      release with subsequent mode of actions. Histamine 1 receptor (H(1) R) and 
      histamine 2 receptor (H(2) R) antagonists are frequently used for the treatment 
      of allergy and gastric acid secretion, respectively, but their antagonism is 
      probably ineffective for migraine. Histamine 3 receptor (H(3) R) and histamine 4 
      receptor (H(4) R) have a threefold higher affinity than H(1) R/H(2) R for 
      histamine and are found almost exclusively on neurons and immune tissues, 
      respectively. H(3) R acts as an autoreceptor or as a heteroreceptor, lowering the 
      release of histamine and other neurotransmitters. This is a potential target for 
      anti-nociception and anti-neurogenic inflammation. To date, several small 
      clinical trials using low dose histamine or N(alpha) -methylhistamine have 
      demonstrated migraine prophylactic efficacy, probably via H(3) R or other 
      undetermined pathways. CONCLUSION: The histamine system interacts with multiple 
      regions in the CNS and may hypothetically modulate the migraine response. Low 
      dose histamine may be a promising option for migraine prevention.
CI  - (c) 2017 American Headache Society.
FAU - Yuan, Hsiangkuo
AU  - Yuan H
AUID- ORCID: 0000-0002-4536-9974
AD  - Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.
FAU - Silberstein, Stephen D
AU  - Silberstein SD
AD  - Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170901
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Neurotransmitter Agents)
RN  - 820484N8I3 (Histamine)
SB  - IM
MH  - Central Nervous System/*metabolism
MH  - Histamine/*metabolism
MH  - Homeostasis
MH  - Humans
MH  - Migraine Disorders/*metabolism/*pathology
MH  - Neurotransmitter Agents/physiology
OTO - NOTNLM
OT  - antihistamine
OT  - histamine
OT  - migraine
OT  - therapeutic
EDAT- 2017/09/02 06:00
MHDA- 2019/03/28 06:00
CRDT- 2017/09/02 06:00
PHST- 2017/07/10 00:00 [received]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/09/02 06:00 [pubmed]
PHST- 2019/03/28 06:00 [medline]
PHST- 2017/09/02 06:00 [entrez]
AID - 10.1111/head.13164 [doi]
PST - ppublish
SO  - Headache. 2018 Jan;58(1):184-193. doi: 10.1111/head.13164. Epub 2017 Sep 1.